This article is more than 5 years old. Information may no longer be current.

Latanoprost patent upheld in New Jersey

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Pfizer has prevailed in a patent infringement suit in which Par Pharmaceutical was seeking approval to market a generic version of latanoprost, according to separate press releases issued by the two companies.

Pfizer noted that Judge Stanley R. Chesler of the U.S. District Court for the District of New Jersey held Pharmacia’s patent on formulations and uses was valid, infringed and enforceable against Par. The court further issued an injunction against Par’s drug application until Pharmacia’s patent expires in 2011.

One of the patents in dispute was deemed not to have been infringed, according to both companies. The court declared the ’368 patent unenforceable due to inequitable conduct on the part of Pharmacia to submit pertinent patent information.

Latanoprost is marketed by Pfizer as Xalatan.